Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
MiNK Therapeutics, Inc. (INKT) had Consolidated Net Income/Loss of $-2.74M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-2.74M |
|
-- |
|
-- |
|
$2.88M |
|
$-2.88M |
|
$0.14M |
|
$-2.74M |
|
$-2.74M |
|
$-2.74M |
|
$-2.74M |
|
|
Consolidated Net Income/Loss |
$-2.74M |
$-2.74M |
|
$-2.88M |
|
$-2.85M |
|
4.80M |
|
4.80M |
|
$-0.57 |
|
$-0.57 |
|
| Balance Sheet Financials | |
$10.02M |
|
$0.35M |
|
$0.35M |
|
$10.38M |
|
$7.29M |
|
-- |
|
$15.78M |
|
$23.06M |
|
$-12.69M |
|
$-12.69M |
|
$-12.69M |
|
4.97M |
|
| Cash Flow Statement Financials | |
$-1.73M |
|
-- |
|
$-2.10M |
|
$13.36M |
|
$9.53M |
|
$-3.83M |
|
$0.63M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
21.62% |
|
21.62% |
|
-26.43% |
|
21.62% |
|
$-2.55 |
|
$-0.36 |
|
$-0.36 |
|